Researchers from the Murdoch Children’s Research Institute (MCRI) have successfully created human blood stem cells in the lab that closely resemble those found in embryos. This breakthrough could significantly impact personalized treatments for leukemia and bone marrow disorders by enabling tailored blood cell transplants. The lab-grown stem cells can be reprogrammed from a patient’s cells, potentially reducing immune rejection and offering scalable solutions for clinical use.
This technology paves the way for revolutionary treatments for blood-related diseases, such as leukemia, by creating patient-specific stem cells for transplantation. Currently, bone marrow transplants require matching donors, which can be time-consuming and carry a risk of immune rejection. The lab-grown stem cells are derived from the patient’s own cells, offering compatibility, reducing rejection risks, and increasing treatment efficiency. These cells are suitable for clinical applications due to their scale and purity, potentially transforming therapies for a range of hematologic diseases.
Nature Reviews Bioengineering
